A Phase 1b/2, With Phase 2 Randomized, Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma

Trial Profile

A Phase 1b/2, With Phase 2 Randomized, Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Jan 2018

At a glance

  • Drugs Olaratumab (Primary) ; Doxorubicin
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 24 Jan 2018 According to Eli Lilly media release, based on the data from this study, Health Canada has issued a Notice of Compliance with Conditions for Olaratumab used in combination with doxorubicin for the treatment of adult patients with soft tissue sarcoma when treatment with radiation or surgery are not options.
    • 19 Oct 2016 Results published in the Media Release
    • 19 Oct 2016 Results published in Eli Lilly and Company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top